Literature DB >> 1947804

Antibiotic treatment in Lyme borreliosis.

A Philipson1.   

Abstract

Before the etiology of Lyme borreliosis became known, its human manifestations were most often treated with penicillin. Treatment was mostly successful, in spite of the fact that lower doses were generally used, but the doses were given with shorter intervals. Lately, other antibiotics have been tried, more or less successfully, but there is still no consensus as to which--if any--antibiotic is superior to others, or if one manifestation of the infection is better treated than another with a particular antibiotic.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1947804

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  5 in total

1.  Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis.

Authors:  M Karlsson; S Hammers; I Nilsson-Ehle; A S Malmborg; B Wretlind
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi.

Authors:  A Kersten; C Poitschek; S Rauch; E Aberer
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

3.  Erythromycin resistance in Borrelia burgdorferi.

Authors:  Darya Terekhova; Marina L Sartakova; Gary P Wormser; Ira Schwartz; Felipe C Cabello
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies.

Authors:  L L Dever; J H Jorgensen; A G Barbour
Journal:  J Clin Microbiol       Date:  1992-10       Impact factor: 5.948

5.  Polymerase chain reaction for detection of Borrelia burgdorferi DNA in skin lesions of early and late Lyme borreliosis.

Authors:  L V von Stedingk; I Olsson; H S Hanson; E Asbrink; A Hovmark
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-01       Impact factor: 3.267

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.